10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      New insights into the antiviral effects of chloroquine

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In a paper published 2 years ago in this journal, some of us described the potentially therapeutic benefits of the quinoline antimalarial chloroquine in viral diseases such as HIV-1/AIDS and severe acute respiratory syndrome (SARS). 1 Chloroquine/hydroxychloroquine has since been adopted to treat HIV-1-infected patients in clinical trials, and new insights into its antiviral activity have been obtained from in-vitro studies. On the HIV/AIDS front, chloroquine (250 mg twice daily) has been administered to HIV-1-infected patients with baseline viral loads over 50 000 copies per mL, in combination with lamivudine (150 mg twice daily) and hydroxyurea (500 mg twice daily) in an ongoing clinical trial in India. 2 Ten out of 18 volunteers had an undetectable viral load at week 24. 2 The median drop in viral load was more than 2·0 log, 2 more than the median 1·5 log drop seen with a nucleoside reverse transcriptase inhibitor (NRTI) and hydroxyurea alone. 3 These results are different from those of another trial in Singapore using didanosine (125–250 mg twice daily), hydroxyurea (500 mg twice daily), and hydroxychloroquine (200 mg twice daily, corresponding to 125 mg of chloroquine). 1 The median drop in viral load was 1·3 log, similar to that induced by a NRTI plus hydroxyurea. Follow-up of these patients at week 144 suggests that the value of hydroxychloroquine may lie in the maintenance of the effects of didanosine/hydroxyurea. 4 The discrepancy between the two studies, besides differences in the design and patients enrolled, probably reflects the different dosages of chloroquine/hydroxychloroquine. Drops in viral load are reported to occur using daily doses of 800 mg of hydroxychloroquine, 1 corresponding to 500 mg of chloroquine (as used in the Indian study), but not using 250 mg of chloroquine daily, 5 corresponding to 400 mg of hydroxychloroquine (as adopted in the Singapore study). Chloroquine/hydroxychloroquine might thus be a valuable option to be tested in low-cost antiretroviral combinations, but correct dosages should be used, considering that the study participants should be regularly monitored to prevent retinopathy. Prospective randomised double-blind placebo studies are also needed to assess the contribution of chloroquine/hydroxychloroquine as part of an antiretroviral regimen. According to new in-vitro results, the antiretroviral effects of chloroquine are attributable to the inhibition of viral particle glycosylation. 6 These effects appeared to be specific, since the chloroquine concentrations effective in vitro neither affected any other step in HIV-1 replication nor were cytotoxic. 6 Our hypothesis that chloroquine might inhibit replication of the SARS coronavirus 1 has been confirmed in two independent in-vitro studies.7, 8 Researchers at the Belgian Catholic University of Leuven found that chloroquine inhibited SARS coronavirus replication with a 50% effective concentration of 8·8 (SE 1·2) μmol/L, within the range of blood concentrations achievable during antimalarial treatment. 7 The dose inducing 50% cytostatic activity was much higher (261·3 [14·5] μmol/L). Time-of-addition experiments indicated that chloroquine affected an early stage of SARS coronavirus replication. 7 Researchers at the Centers for Disease Control and Prevention (Atlanta, GA, USA) reported potent anti-SARS coronavirus effects of chloroquine in vitro, attributable to a deficit in the glycosylation of the SARS coronavirus receptor ACE2. 8 Again, the antiviral drug concentrations were not cytotoxic. If animal models confirm these results, chloroquine might represent a valuable therapeutic option if SARS re-emerges. The broad spectrum antiviral effects of chloroquine deserve particular attention in a time in which the world is threatened by the possibility of a new influenza pandemic, and the availability of effective drugs would be fundamental during evaluation of an effective vaccine. The effect of chloroquine against replication of Orthomyxoviridae has long been known.9, 10 Inhibitory effects of chloroquine on both type A and B influenza viruses have been described.9, 10 We are currently investigating the inhibitory effect of chloroquine on the H5N9/A/chicken/Italy/9097/97 avian influenza virus, recently isolated from poultry in Italy. 11 Depending on the viral challenging doses and the methods adopted to detect the antiviral effects, the inhibitory concentrations fell within the 0·5–10 μmol/L range—ie, clinically achievable in plasma during malaria treatment (LDT, AS, ID, RC, and AC, unpublished data). If these effects are confirmed, chloroquine would deserve to be tested against the H5N1 type A avian influenza virus, currently a matter of serious concern for public health. As discussed above, glycosylation inhibition might represent a major mechanism for the antiviral effects of chloroquine, suggesting that specific interactions of chloroquine with sugar-modifying enzymes or glycosyltransferases may occur within human cells (figure ). Chloroquine was recently shown to inhibit quinone reductase 2, 13 a structural neighbour of UDP-N-acetylglucosamine 2-epimerases, 14 which are involved in sialic acid biosynthesis. If chloroquine should indeed inhibit the biosynthesis of sialic acid, this effect could explain not only the effects of chloroquine on HIV and SARS coronavirus (sialic acid moieties are present in HIV-1 glycoproteins and SARS coronavirus receptor ACE2), but also the in-vitro effects on orthomyxoviruses (which use sialic acid moieties as receptors 15 ). These effects deserve further investigation, in that they may lead to new strategies controlling the replication of several viruses. Figure Can chloroquine interact with sugar-modifying enzymes? This computer-assisted simulation of ligand/protein docking by use of the program GOLD 12 indicates that chloroquine (red) fits to the active site of UDP-N-acetylglucosamine 2-epimerase (grey). This evidence suggests that chloroquine could inhibit the enzyme that catalyses the rate-determining step in the sialic acid biosynthetic pathway.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines.

          Quinone oxidoreductase 2 (QR2) purified from human red blood cells was recently shown to be a potential target of the quinoline antimalarial compounds [Graves et al., (2002) Mol. Pharmacol. 62, 1364]. QR2 catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or N-ribosylated nicotinamides. To investigate the mechanism and consequences of inhibition of QR2 by the quinolines further, we have used steady-state and transient-state kinetics to define the mechanism of QR2. Importantly, we have shown that QR2 when isolated from an overproducing strain of E. coli is kinetically equivalent to the enzyme from the native human red blood cell source. We observe ping-pong kinetics consistent with one substrate/inhibitor binding site that shows selectivity for the oxidation state of the FAD cofactor, suggesting that selective inhibition of the liver versus red blood cell forms of malaria may be possible. The reductant N-methyldihydronicotinamide and the inhibitor primaquine bind exclusively to the oxidized enzyme. In contrast, the inhibitors quinacrine and chloroquine bind exclusively to the reduced enzyme. The quinone substrate menadione, on the other hand, binds nonspecifically to both forms of the enzyme. Single-turnover kinetics of the reductive half-reaction are chemically and kinetically competent and confirm the inhibitor selectivity seen in the steady-state experiments. Our studies shed light on the possible in vivo potency of the quinolines and provide a foundation for future studies aimed at creating more potent QR2 inhibitors and at understanding the physiological significance of QR2.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Antihistaminics, local anesthetics, and other amines as antiviral agents.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mechanism of uncoating of influenza B virus in MDCK cells: action of chloroquine.

              Exposure of influenza B virus-infected MDCK cells to chloroquine at the time of infection resulted in significant inhibition of infection. The appearance of input virus in the intracellular vesicles was not affected in the presence of the drug, but primary transcription of the virus genome did not occur. Chloroquine caused a rapid rise in the pH inside the lysosomes of MDCK cells, to 6.5 from the physiological pH 5.6. In contrast, exposure of infected cells incubated in acidic medium (pH 6.0) to chloroquine did not cause an increase in lysosomal pH and this low pH treatment during the chloroquine-sensitive phase was followed by virus production. Influenza B virus induced haemolysis of chick erythrocytes at low pH values (5.0 to 5.9) which was associated with cell-cell membrane fusion. It is likely that chloroquine prevents the uncoating of influenza B virus by increasing the lysosomal pH above the critical value required for inducing fusion between the virus envelope and the lysosomal membrane.
                Bookmark

                Author and article information

                Contributors
                Journal
                Lancet Infect Dis
                Lancet Infect Dis
                The Lancet. Infectious Diseases
                Elsevier Ltd.
                1473-3099
                1474-4457
                24 January 2006
                February 2006
                24 January 2006
                : 6
                : 2
                : 67-69
                Affiliations
                [a ]Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Rome, Italy
                [b ]Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Rome
                [c ]Department of Food and Animal Health, Istituto Superiore di Sanità, Rome
                Author notes
                [* ]Correspondence to: Dr Andrea Savarino, Laboratory of Viral Immunology, Department of Infectious Diseases, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, I-00168 Rome, Italy. Tel +39 06 30155374; fax +39 06 3054519 asavarino@ 123456medscape.com
                Article
                S1473-3099(06)70361-9
                10.1016/S1473-3099(06)70361-9
                7129107
                16439323
                0cff267e-8e74-4fa2-abe0-f349a84535bb
                Copyright © 2006 Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Article

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article